Spectral Medical Announces Appointment of Blair McInnis as CFO
21 März 2022 - 12:30PM
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:
EDT), a late stage theranostic company advancing
therapeutic options for sepsis and septic shock, as well as
commercializing a new proprietary platform targeting the renal
replacement therapy market through its wholly-owned subsidiary
Dialco Medical Inc. (Dialco), today announced the appointment of
Blair McInnis as Chief Financial Officer, effective April 4, 2022.
Mr. McInnis assumes the role of Chief Financial Officer from Chris
Seto, who will continue as Chief Executive Officer of the Company.
Mr. McInnis brings 15 years of corporate finance
and reporting experience. Most recently, he served as Vice
President Finance at SMTC Corporation, a provider of global
electronics manufacturing services with annualized revenues in
excess of $450 million, where he managed financial reporting,
budgeting, treasury management and forecasting for the
organization. During his tenure, he helped oversee the financial
aspects of the acquisition and privatization of the Company by
H.I.G. Capital, a leading global private equity firm, prior to
which, SMTC was listed on Nasdaq. Before joining in SMTC in 2013,
Mr. McInnis served as Assurance Manager at Ernst & Young LLP,
where he managed audits of both private and public companies, and
serviced a broad range of industries including healthcare,
manufacturing, logistics, telecommunications, and more. He is a
Certified Public Accountant and earned his Bachelor of Commerce
from Laurentian University in 2007.
Chris Seto, CEO of Spectral, commented, “I am
delighted to welcome Blair to the senior management team. He brings
an impressive track record across corporate finance, capital
markets, M&A, budgeting, and compliance, as well as experience
with Nasdaq listed companies. We look forward to his contributions
as we prepare for our next phase of growth, including advancement
of our PMX platform, as well as our SAMI and DIMI devices.
Moreover, we believe his appointment further illustrates our
continued commitment to careful management of expenses and
maintaining the highest levels of corporate governance.”
About Spectral
Spectral is a Phase III company seeking U.S. FDA
approval for its unique product for the treatment of patients with
septic shock, Toraymyxin™ (“PMX”). PMX is a
therapeutic hemoperfusion device that removes endotoxin, which can
cause sepsis, from the bloodstream and is guided by the Company’s
Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic
for the risk of developing sepsis.
PMX has been approved for therapeutic use in
Japan and Europe, and has been used safely and effectively on more
than 340,000 patients to date. In March 2009, Spectral obtained the
exclusive development and commercial rights in the U.S. for PMX,
and in November 2010, signed an exclusive distribution agreement
for this product in Canada. Approximately 330,000 patients are
diagnosed with severe sepsis and septic shock in North America each
year.
Spectral, through its wholly owned subsidiary,
Dialco Medical Inc., is also commercializing a new set of
proprietary platforms addressing renal replacement therapy
(“RRT”) across the dialysis spectrum. SAMI is
targeting the acute RRT market, while DIMI is targeting the chronic
RRT market. Dialco is currently pursuing regulatory approval for
U.S. in-home use of DIMI, which is based on the same RRT platform
as SAMI, but will be intended for home hemodialysis use. DIMI
recently received its FDA 510k clearance for use in hospital and
clinical settings, and obtained its Health Canada license for use
within Canadian hospitals, clinics and in home.
Spectral is listed on the Toronto Stock Exchange
under the symbol EDT. For more information, please visit
www.spectraldx.com.
Forward-looking statement
Information in this news release that is not
current or historical factual information may constitute
forward-looking information within the meaning of securities laws.
Implicit in this information, particularly in respect of the future
outlook of Spectral and anticipated events or results, are
assumptions based on beliefs of Spectral's senior management as
well as information currently available to it. While these
assumptions were considered reasonable by Spectral at the time of
preparation, they may prove to be incorrect. Readers are cautioned
that actual results are subject to a number of risks and
uncertainties, including the availability of funds and resources to
pursue R&D projects, the successful and timely completion of
clinical studies, the ability of Spectral to take advantage of
business opportunities in the biomedical industry, the granting of
necessary approvals by regulatory authorities as well as general
economic, market and business conditions, and could differ
materially from what is currently expected.
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
Contact:
Mr. Chris Seto |
Mr. Ali Mahdavi |
David Waldman/Natalya Rudman |
CEO |
Capital Markets & Investor
Relations |
US Investor Relations |
Spectral Medical Inc. |
Spinnaker Capital Markets
Inc. |
Crescendo Communications,
LLC |
416-626-3233 ext. 2004 |
416-962-3300 |
212-671-1020 |
cseto@spectraldx.com |
am@spinnakercmi.com |
edt@crescendo-ir.com |
Spectral Medical (TSX:EDT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Spectral Medical (TSX:EDT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024